‘Samsung Biologics’ is Looking For a Place in The Field of Biotechnology
Technology giant Samsung now strides in the field biotechnology with the ‘Samsung Biologics’.South Korean company made a presentation about this subject and shared important information about plans. Samsung Chairman Lee Kun-hee attended to meeting and he announced that Samsung aims to produce biological drugs comprising living cells and blood components rather than chemicals.
Technology giant Samsung now strides in the field biotechnology with the ‘Samsung Biologics’.South Korean company made a presentation about this subject and shared important information about plans.
Samsung Chairman Lee Kun-hee attended to meeting and he announced that Samsung aims to produce biological drugs comprising living cells and blood components rather than chemicals.Samsung wants to develop useful drugs to diseases such as arthritis especially cancer and company intends to use computer chip producing experience in this field.In fact, Samsung aims to become the largest company in this field bringing the production process even more streamlined and efficient.Samsung Biologics has spent 720 million dollars to build 180 thousand liters facility and it is known that Bristol-Myers Squibb which is the another company in this market has spent 900 million dollars for 90 thousand liters facility last year.
İf this big cost difference in just one year originates from Samsung’s ability, we can say that the company will become an assertive opponent in this field.Samsung Biologics CEO Kim Tae-Han said that facility can produce non-stop throughout the year.Other three facilities of Samsung Biologics will be completed in 2018, and South Korean company will have a production capacity of 360 thousand liters in total.
South Korean President Park Geun-Hye also attended the meeting and it shows that how Samsung is serious about this issue.
Related Coverage
- Can Elon Musk Make A Solar Success With His Solar Roof Proposal?
- Researches Turned Skin Cells into Heart and Brain Cells using Drugs
- VW’s Aggressive Electric-Car Plans To Compete With Tesla
- New Laser Imaging System Shows the Structure of Biological Tissue and The Dynamic Activity
- Samsung and Baidu Want to Make a Autonomous Car
Don't miss new tech stories on Google
Add TrendinTech once in the Google app and our stories appear in your news suggestions.
Daniel Okafor
Daniel Okafor is the Senior AI Reporter at TrendinTech, where he covers large language models, machine learning research and the practical use of artificial intelligence across business and government. He previously reported on artificial intelligence for MIT Technology Review, covering the labs behind the current generation of frontier models and the policy debates in Washington and Brussels. Daniel holds a Master of Science in Machine Learning from Carnegie Mellon University and follows the research community closely, attending NeurIPS and ICML each year to speak with the people behind the papers. He has a particular interest in evaluation: how models are benchmarked, where those benchmarks fail and what that means for the companies betting on them.
All stories by Daniel Okafor (316)